Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.
The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.
NHS England’s Long Term Plan puts much emphasis on better use of diagnostic tools in health-care delivery. The UK medtech industry is now pressing for a strategy to ensure that these technologies are factored into all patient pathways. It says the data derived will be used to improve patient outcomes and system efficiency.
Audiovisual media solutions provider Sony Corp. plays a largely unseen role in the success of end-user-facing capital equipment that manufacturers serve to the medtech sector. Product marketing manager for Sony Europe Healthcare Solutions, John Herman, explains Sony’s role in the industry, and how it is stepping up its focus on 4K imaging.
Risk management was the thread running through the ABHI’s annual regulatory conference. But the irrepressible theme of the MDR was the main draw for the 200 attendees, even though the MHRA and industry are still unaware of the shape of the UK’s future relationship with the EU.
The consensus among the UK MHRA, the national medtech industry and notified bodies remains that convergence of regulatory systems is the preferred route for the UK once it has left the EU. Meanwhile, the regulator is planning for all eventualities, as a recent parliamentary forum on the post-Brexit regulatory landscape heard.